

6 US states accuse opioid maker Purdue of fueling overdoses

15 May 2018, by Ken Ritter



This Feb. 19, 2013, file photo shows OxyContin pills arranged for a photo at a pharmacy in Montpelier, Vt. Nevada and five other states are filing new lawsuits alleging that a pharmaceutical company used deceptive marketing to boost drugs sales that fueled opioid overdose deaths. Nevada state Attorney General Adam Paul Laxalt alleges in a civil complaint filed Tuesday, May 15, 2018, that Purdue Pharma minimized risks and overstated benefits of long-term use of narcotic opioids including OxyContin. (AP Photo/Toby Talbot, File)

Six U.S. states on Tuesday sued the maker of the opioid OxyContin of using deceptive marketing to boost drug sales that fueled opioid overdose deaths.

Drugmaker Purdue Pharma minimized risks and overstated benefits of long-term use of narcotic opioids, according to a civil complaint filed in Nevada state court in Las Vegas.

"Purdue's deception lined the pockets of its owners and led to the deaths and hospitalization of thousands of Nevadans," Nevada state Attorney General Adam Laxalt said in a statement.

Similar suits were being filed in Florida, North

Carolina, North Dakota, Tennessee and Texas, Laxalt aide Monica Moazez said.

In Tennessee, Attorney General Herbert Slatery alleged that Purdue violated a 2007 settlement with his state and "knew patients were dying from overdoses and that its drugs were being illegally sold to non-patients."

Purdue, based in Stamford, Connecticut, denied the claims and said it will defend itself.

Company spokesman Bob Josephson said in an email statement that the lawsuits followed months of negotiations with state officials to address the <u>opioid</u> crisis. He said the lawsuits signaled costly and protracted litigation.

Slatery, who has led a 40-state probe of opioid manufacturers and distributors, said his state's complaint was submitted in Knoxville under temporary seal to protect the confidentiality of information that Purdue provided to investigators.



This Tuesday, May 8, 2007 file photo shows the Purdue Pharma offices in Stamford, Conn. Nevada and five other states are filing new lawsuits alleging that a pharmaceutical company used deceptive marketing to boost drugs sales that fueled opioid overdose deaths.



Nevada state Attorney General Adam Paul Laxalt alleges in a civil complaint filed Tuesday, May 15, 2018, that Purdue Pharma minimized risks and overstated benefits of long-term use of narcotic opioids including OxyContin. (AP Photo/Douglas Healey, File)

The probe and talks with the company are continuing, said Leigh Ann Apple Jones, spokeswoman for Slatery.

In Florida, Attorney General Pam Bondi added four other opioid manufacturers and four distributors to her state's complaint.

"We are in the midst of a national opioid crisis claiming 175 lives a day nationally and 15 lives a day in Florida," Bondi said in a statement. She accused the companies of "profiting from the pain and suffering of Floridians."

Laxalt, in Nevada, accused Purdue Pharma of downplaying serious risks of addiction and overstating the effectiveness of doctors' ability to manage patients' addiction.

In Texas, Attorney General Ken Paxton also alleged the company misrepresented that there is no "ceiling dose" of their <u>opioid drugs</u>, and that doctors and patients could increase dosages indefinitely without risk.

The lawsuits come about a month after a change-ofcourse by a federal judge in Cleveland who had been encouraging companies and <u>states</u> to settle hundreds of lawsuits filed by local governments alleging overuse of prescription opioid painkillers.

The judge has scheduled three trials in Ohio beginning next year.

© 2018 The Associated Press. All rights reserved. APA citation: 6 US states accuse opioid maker Purdue of fueling overdoses (2018, May 15) retrieved 22 September 2022 from <u>https://medicalxpress.com/news/2018-05-states-accuse-opioid-maker-purdue.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.